check_circleStudy Completed

Ophthalmology, Macular Degeneration

Bayer Identifier:

20285

ClinicalTrials.gov Identifier:

NCT04067583

EudraCT Number:

Not Available

EU CT Number:

Not Available
A follow-up physician survey to evaluate physician knowledge of safety and safe use information for Aflibercept administered by intravitreal injection in Europe

Trial purpose

With this follow up physician survey researcher want to collect the same data from all participants of the study using a highly structured questionnaire. The questionnaire will gather information related to physician characteristics and experience with Aflibercept, as well as assess physicians’ knowledge and understanding of storage and preparation, proper injection technique, and the risks associated with Aflibercept injection into the eye (intravitreal injection). Analysis will be done using descriptive statistics.

Key Participants Requirements

Sex

All

Age

NaN - N/A
  • - Has signed informed consent
    - Is a licensed and practicing ophthalmologist
    - Has prescribed and/or administered aflibercept to at least one patient in the past 6 months

  • - None

Trial summary

Enrollment Goal
454
Trial Dates
October 2019 - April 2020
Phase
N/A
Could I Receive a placebo
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Many locationsMany locations, Germany

Primary Outcome

  • Percentage of physicians responding correctly to each individual knowledge question
    date_rangeTime Frame:
    Up to 1 year

Trial design

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe: A Follow-up Physician Survey
Trial Type
Observational
Intervention Type
Other
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here to find results for studies related to Bayer products